title: [Clinical features of cytopenia with bone marrow hypoplasia in children: an analysis of 100 cases].
abstract: OBJECTIVE
  To summarize the clinical features of cytopenia with bone marrow hypoplasia in 100 children and to investigate an effective treatment regimen for myelodysplastic syndrome (MDS) in children.
  
  
  METHODS
  A retrospective analysis was performed on the clinical data of 100 children non-randomly selected from Japan and China who were diagnosed with cytopenia with bone marrow hypoplasia between 2006 and 2011. The data of patients from China were subjected to prognostic analysis.
  
  
  RESULTS
  There was no significant difference in the proportion of MDS cases and acquired aplastic anemia (AA) cases between the Japanese and Chinese children. Of the 100 patients, there were 29 cases of acquired AA, 58 cases of refractory cytopenia of childhood (RCC) and 13 cases of refractory cytopenia with multilineage dysplasia (RCMD). There were significant differences in reticulocyte absolute value in peripheral blood and degree of bone marrow proliferation among the three patient groups (P<0.05). The patients from China were followed up for 16-70 months (median, 41 months). After being treated with cyclosporine (CsA) combined with stanozolol, the patients with AA had response rates of 25% and 75%, the patients with RCC had response rates of 47.1% and 82.4%, and the patients with RCMD had response rates of 60% and 60% respectively at 3 and 6 months after treatment.
  
  
  CONCLUSIONS
  There are significant differences in reticulocyte absolute value in peripheral blood and degree of bone marrow proliferation among patients with RCC, RCMD and acquired AA. CsA combined with stanozolol has a good therapeutic efficacy in the treatment of acquired AA and hypoplastic MDS in children, but studies of more cases and a longer follow-up duration are needed.
authors.affiliation: Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China.
authors.forename: Wen-Yu
authors.initials: WY
authors.lastname: Yang
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Chen
authors.forename: Pei-Hong
authors.initials: PH
authors.lastname: Zhang
authors.forename: Asahito
authors.initials: A
authors.lastname: Hama
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ito
authors.forename: Seiji
authors.initials: S
authors.lastname: Kojima
authors.forename: Xiao-Fan
authors.initials: XF
authors.lastname: Zhu
mesh_terms: D000293:Adolescent; D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D010198:Pancytopenia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: D016572:Cyclosporine